Why the study?
Does the class of initial antihypertensive drug affect treatment persistence and healthcare costs in new users?
Does the class of initial antihypertensive drug affect treatment persistence and healthcare costs in new users?
Nearly two-thirds of patients initiating antihypertensive therapy become non-persistent within one year, highlighting a major gap in hypertension management.
No abstract yet. The journal hasn't published one we can show.
No takes yet. Share an insight, caveat, or question.
Esposti et al. (2002) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: